Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
5(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
20%
Ph phase_1
5
50%
Ph phase_3
3
30%

Phase Distribution

5

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
3(30.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(7)
Completed(3)

Detailed Status

Recruiting3
Completed3
Active, not recruiting2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (50.0%)
Phase 22 (20.0%)
Phase 33 (30.0%)

Trials by Status

recruiting330%
active_not_recruiting220%
completed330%
not_yet_recruiting220%

Recent Activity

5 active trials
Showing 5 of 10
completedphase_1

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

NCT05835752
active_not_recruitingphase_1

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

NCT07362030
not_yet_recruitingphase_3

A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

NCT07139535
not_yet_recruitingphase_3

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

NCT07139548
active_not_recruitingphase_2

A Study of RAY1225 in Participants With Type 2 Diabetes

NCT06254274
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05835752Phase 1

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

Completed
NCT07362030Phase 1

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

Active Not Recruiting
NCT07139535Phase 3

A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Not Yet Recruiting
NCT07139548Phase 3

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

Not Yet Recruiting
NCT06254274Phase 2

A Study of RAY1225 in Participants With Type 2 Diabetes

Active Not Recruiting
NCT06893016Phase 3

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

Recruiting
NCT06254261Phase 2

A Study of RAY1225 in Participants With Obesity

Recruiting
NCT06577415Phase 1

A Study of RAY1225 in Participants With Impaired Liver Function

Recruiting
NCT06577428Phase 1

A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes

Completed
NCT06613763Phase 1

A Study of RAY1225 in Participants With Impaired Kidney Function

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10